← Leaderboards
Yvonne Margaret Saenger
Albert Einstein College Of Medicine
$3,946,350
Attributed
$6,092,383
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,342,383 · 4
FDA$750,000 · 1
By mechanism
R01$3,251,736 · 2
K12$1,425,480 · 1
UH3$1,050,317 · 1
UH2$364,850 · 1
Top collaborators
- Rui Chang5 shared
- Amit Verma3 shared
- John J Krolewski2 shared
Most similar at Albert Einstein College Of Medicine
Same institution · by research overlap
- Derek Major Huffman$7,446,355
- Rui Chang$4,628,013
- Evripidis Gavathiotis$9,805,575
- Mark H. Einstein$5,034,799
- Aldrin Enrique Molero$4,631,825
Others in their field
Other Emerging Leaders on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Yunda Huang · Fred Hutchinson Cancer Center$65,418,952
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Leonard Freedman · Leidos Biomedical Research, Inc.$20,851,347
- Kristin Aillon · Midwest Research Institute$18,958,174
Research focus
Exposure ToPrognostic MarkerAdjuvant TherapyMessenger RnaParaffin EmbeddingInterobserver VariabilityClinical ApplicationImmuneHigh RiskGenesImmunologic MarkersOperative Surgical ProceduresInterferonsBiological MarkersMelanomaCessation Of LifeCohortCd8b1 GeneAdjuvantMorphologyFormalinBritish ColumbiaAdjuvant StudyProspective
Grant awards (16)
Montefiore Einstein Clinical Oncology Training Program in the Bronx$691,824
K12 · FY2025 · CA
Applying pathomics to establish a biosignature for aggressive skin melanoma$607,163
R01 · FY2025 · CA · contact PI
Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx$707,995
K12 · FY2024 · CA
Applying pathomics to establish a biosignature for aggressive skin melanoma$584,380
R01 · FY2024 · CA · contact PI
A prognostic mRNA immune signature for resected stage II-III melanoma$315,254
UH3 · FY2024 · CA · contact PI
Applying pathomics to establish a biosignature for aggressive skin melanoma$616,736
R01 · FY2023 · CA · contact PI
A prognostic mRNA immune signature for resected stage II-III melanoma$332,806
UH3 · FY2023 · CA · contact PI
Diversity-focused Montefiore Einstein Clinical Oncology Training Program in the Bronx$25,661
K12 · FY2023 · CA
A prognostic mRNA immune signature for resected stage II-III melanoma$402,257
UH3 · FY2022 · CA · contact PI
Applying pathomics to establish a biosignature for aggressive skin melanoma$1
R01 · FY2022 · CA · contact PI
Applying pathomics to establish a biosignature for aggressive skin melanoma.$693,456
R01 · FY2021 · CA · contact PI
Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)$250,000
R01 · FY2020 · FD · contact PI
A prognostic mRNA immune signature for resected stage II-III melanoma$167,236
UH2 · FY2020 · CA · contact PI
Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)$250,000
R01 · FY2019 · FD · contact PI
A prognostic mRNA immune signature for resected stage II-III melanoma$197,614
UH2 · FY2019 · CA · contact PI
Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)$250,000
R01 · FY2018 · FD · contact PI